Test Price
1,200 AED✅ Home Collection Available
Immunohistochemistry Microsatellite Instability (MSI) Panel in UAE – 1200 AED – DNA Labs UAE
Executive Summary & Core Metrics
- ✔️ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✔️ Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for all FFPE blocks and biopsy slides.
- ✔️ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- ✔️ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Immunohistochemistry Microsatellite Instability (MSI) Panel is a combined immunohistochemical and molecular test that evaluates mismatch repair (MMR) protein expression (MLH1, MSH2, MSH6, PMS2) and microsatellite instability status — a critical biomarker for Lynch syndrome screening, colorectal and endometrial cancer prognosis, and immunotherapy (PD-1/PD-L1) eligibility. The test integrates monoclonal antibody-based IHC with confirmatory PCR-STR fragment analysis using Bethesda panel markers to deliver definitive MSI classification.
| Feature | Our MSI Panel (Next‑Gen) | Standard IHC Only |
|---|---|---|
| Precision | IHC + confirmatory PCR‑STR fragment analysis | IHC staining only; risk of false‑negatives |
| Method | Monoclonal antibodies + capillary electrophoresis (Bethesda panel markers) | Immunoperoxidase DAB detection |
| Turnaround | 5–7 days (block/tissue) with digital report | 3–5 days, often without MSI confirmation |
Physician Insight & Safety Protocols
“The MSI panel result should always be interpreted alongside the patient’s clinical history, family cancer profile, and histopathology to guide Lynch syndrome surveillance, chemotherapy, or immunotherapy decisions. A positive MSI‑high result in colorectal or endometrial tumours can redefine treatment pathways and hereditary risk counselling. I encourage patients to discuss all findings with their treating oncologist or genetic counsellor.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Safety & Clinical Advisory
⚠️ Medication Safety & Clinical Warning
Do not discontinue prescribed medication without consulting your doctor. MSI testing does not require alteration of current therapies; however, results may inform future treatment decisions that should be managed by your oncology team.
Exclusion Criteria & Red Flags
- No patient exclusions for the test itself; however, the biopsy site must be fully healed before sample submission.
- Inadequate or improperly fixed tissue (e.g., decalcified specimens) may yield indeterminate results.
- Emergency Red Flags: If you experience fever, excessive bleeding, swelling, or severe pain at the biopsy site, seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is an MSI panel and why is it needed?
The MSI panel determines whether a tumour exhibits microsatellite instability, a genomic hallmark that can indicate Lynch syndrome, predict response to immunotherapy, and guide chemotherapy decisions in colorectal and endometrial cancers.
2. How is the sample collected and what preparation is needed?
A tumour tissue sample (FFPE block or biopsy in formalin) is required; no fasting or medication changes are needed. Please provide a copy of the histopathology report, biopsy site details, and clinical history. Our secure medical courier service arranges solid tissue specimen retrieval from your hospital or clinic.
3. How long until I receive my results?
Results are ready in 5 days for FFPE blocks, 5 days for tissue biopsies, and up to 7 days for large/complex specimens, with a digital report and optional teleconsultation.
4. What are the pre-requirements for sample submission?
Submit tumour tissue in 10% formal‑saline or a formalin‑fixed paraffin‑embedded (FFPE) block; ship at room temperature. Always attach a copy of the histopathology report, biopsy site details, and clinical history.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data processing, storage, and transfer. All clinical health information is handled in compliance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring end‑to‑end encryption, access controls, and audit trails. Patient consent and clinical safety protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing informed consent and medico‑legal accountability across all diagnostic procedures.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry Microsatellite Instability (MSI) Panel |
| Price (AED) | 1,200 AED |
| Turnaround Time | 5–7 working days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block / Biopsy Slides |
| Methodology Used | Immunohistochemistry (IHC) with confirmatory PCR-STR Fragment Analysis (Bethesda Panel) |
| ICD-10-CM Code | C18.9, Z80.3 |
| LOINC Code | 81695-1 |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians